A Human SARS-CoV Neutralizing Antibody Against Epitope on S2 Protein

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2005 Jun 9

PMID 15939399

Citations 68

Authors

Jinzhu Duan

Xiyun Yan

Xueming Guo

Wuchun Cao

Wei Han

Cai Qi

Jing Feng

Dongling Yang

Guangxia Gao

Gang Jin

Affiliations

Soon will be listed here.

Abstract

An immune antibody phage-display library was constructed from B cells of SARS convalescent patients. More than 80 clones were selected from the library by using the whole inactivated SARS-CoV virions as target. One human scFv, B1, was characterized extensively. The B1 recognized SARS pseudovirus in vivo and competed with SARS sera for binding to SARS-CoV with high affinity (equilibrium dissociation constant, K(d) = 105 nM). The B1 also has potent neutralizing activities against infection by pseudovirus expressing SARS-CoV S protein in vitro. Finally, we found that the B1 recognized an epitope on S2 protein, especially within amino acids 1023-1189 of S2 protein. This study not only first made a human neutralizing antibody, which recognized an epitope on S2 protein like natural antibody in sera, but also may help us to better understand the immunological characteristics of SARS protein and SARS vaccine design.

Citing Articles

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals.

Vilibic-cavlek T, Stevanovic V, Kovac S, Borko E, Bogdanic M, Miletic G Antibodies (Basel). 2023; 12(4).

PMID: 37873858 PMC: 10594469. DOI: 10.3390/antib12040061.

COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.

Bostanghadiri N, Ziaeefar P, Mofrad M, Yousefzadeh P, Hashemi A, Darban-Sarokhalil D Biomed Res Int. 2023; 2023:1879554.

PMID: 37674935 PMC: 10480030. DOI: 10.1155/2023/1879554.

Detection of SARS-CoV-2 Antibodies: Comparison of Enzyme Immunoassay, Surrogate Neutralization and Virus Neutralization Test.

Vilibic-cavlek T, Bogdanic M, Borko E, Hruskar Z, Zilic D, Ferenc T Antibodies (Basel). 2023; 12(2).

PMID: 37218901 PMC: 10204460. DOI: 10.3390/antib12020035.

Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19.

Oliveira I, Ferreira I, Jacob B, Cardenas K, Cerni F, Baia-Da-Silva D Toxins (Basel). 2023; 15(2).

PMID: 36828473 PMC: 9967918. DOI: 10.3390/toxins15020159.

Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.

Klingler J, Lambert G, Bandres J, Emami-Gorizi R, Nadas A, Oguntuyo K iScience. 2022; 25(12):105608.

PMID: 36406863 PMC: 9666267. DOI: 10.1016/j.isci.2022.105608.

References

Pearson H, Clarke T, Abbott A, Knight J, Cyranoski D . SARS: what have we learned?. Nature. 2003; 424(6945):121-6. PMC: 7095391. DOI: 10.1038/424121a. View

Holmes K . SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest. 2003; 111(11):1605-9. PMC: 156116. DOI: 10.1172/JCI18819. View

DeHart J, Andersen J, Zimmerman E, Ardon O, An D, Blackett J . The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. J Virol. 2005; 79(3):1389-96. PMC: 544104. DOI: 10.1128/JVI.79.3.1389-1396.2005. View

Drosten C, Gunther S, Preiser W, van der Werf S, Brodt H, Becker S . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1967-76. DOI: 10.1056/NEJMoa030747. View

Wang Y, Li Y, Xu G, Dong X, Yang X, Feng Z . Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot. Clin Immunol. 2004; 113(2):145-50. PMC: 7106230. DOI: 10.1016/j.clim.2004.07.003. View

Soo Y, Cheng Y, Wong R, Hui D, Lee C, Tsang K . Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10(7):676-8. PMC: 7129386. DOI: 10.1111/j.1469-0691.2004.00956.x. View

He Y, Zhou Y, Wu H, Luo B, Chen J, Li W . Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004; 173(6):4050-7. DOI: 10.4049/jimmunol.173.6.4050. View

Sblattero D, Bradbury A . A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology. 1998; 3(4):271-8. DOI: 10.1016/s1380-2933(97)10004-5. View

Li G, Chen X, Xu A . Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med. 2003; 349(5):508-9. DOI: 10.1056/NEJM200307313490520. View

10.

Sblattero D, Bradbury A . Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol. 2000; 18(1):75-80. DOI: 10.1038/71958. View

11.

Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G . Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000; 296(1):57-86. DOI: 10.1006/jmbi.1999.3444. View

12.

Song H, Seo M, Stadler K, Yoo B, Choo Q, Coates S . Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol. 2004; 78(19):10328-35. PMC: 516425. DOI: 10.1128/JVI.78.19.10328-10335.2004. View

13.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

14.

Giroglou T, Cinatl Jr J, Rabenau H, Drosten C, Schwalbe H, Doerr H . Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol. 2004; 78(17):9007-15. PMC: 506966. DOI: 10.1128/JVI.78.17.9007-9015.2004. View

15.

Lin Y, Yan X, Cao W, Wang C, Feng J, Duan J . Probing the structure of the SARS coronavirus using scanning electron microscopy. Antivir Ther. 2004; 9(2):287-9. View

16.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

17.

Ho T, Wu S, Cheng S, Wei Y, Huang S, Hsiang C . Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun. 2004; 313(4):938-47. PMC: 7111049. DOI: 10.1016/j.bbrc.2003.11.180. View

18.

Han D, Kim H, Kim Y, Poon L, Cho M . Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 2004; 326(1):140-9. PMC: 7127165. DOI: 10.1016/j.virol.2004.05.017. View

19.

van den Brink E, Ter Meulen J, Cox F, Jongeneelen M, Thijsse A, Throsby M . Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005; 79(3):1635-44. PMC: 544131. DOI: 10.1128/JVI.79.3.1635-1644.2005. View

20.

Wang Z, Jin G . A label-free multisensing immunosensor based on imaging ellipsometry. Anal Chem. 2003; 75(22):6119-23. DOI: 10.1021/ac0347258. View